Growth Factor News and Research

RSS

Researchers discover molecule to fight age-related muscle decline

Skeletal muscle is one of the first tissues to decline with age. This decline can lead to weakness, scarring, fat accumulation inside muscle, and the loss of fast-twitch muscle fibers that are important for quick and powerful movements.

24 Jul 2026

Thymulin curbs age-related inflammation and slows breast tumors in mice

Thymulin reduced age-associated inflammatory myeloid cells and slowed breast-tumor growth in aged mice by suppressing NF-κB signaling. The peptide also restored anti-PD-L1 responsiveness in aged mouse models, while human cell and tumor data supported an age-linked inflammatory myeloid profile.

23 Jul 2026

Study reveals how adolescent brain remodeling reshapes memory retrieval

Scientists have long known that the human brain continues developing well beyond the teenage years, with important changes involving decision-making and emotional regulation extending into the mid-to-late 20s.

17 Jul 2026

Timing of regenerative cues may be key to better healing from injury

For decades, medicine has chased a simple but elusive goal of delivering the right drug to the right place at the right time.

16 Jul 2026

Researchers rank 11 preeclampsia therapies as top candidates for further development

Researchers ranked 83 preclinical candidates for preventing or treating preeclampsia and eclampsia, identifying 11 as having high potential for further development. The analysis also revealed limited target diversity, moderate bias, inactive programs, and animal models that may not fully represent human pregnancy

15 Jul 2026

Blocking ZFP384 protein extends brain repair window after stroke

Blocking the activity of ZFP384 can prolong the brain’s endogenous repair functions after stroke, report researchers in a collaborative study.

13 Jul 2026

EGFR inhibitors may overcome chemotherapy resistance in glioblastoma treatment

Treating glioblastoma with a class of drugs known as EGFR inhibitors made this cancer more sensitive to chemotherapy, suggests a study in preclinical models co-led by researchers at UT Southwestern Medical Center and the University of Alabama at Birmingham.

12 Jul 2026

GLP-1RAs linked to lower risk of amputation in diabetes with PAD

Research indicates GLP-1RAs may decrease limb complications in type 2 diabetes with PAD, though more randomized studies are required to confirm efficacy.

10 Jul 2026

Bio-Techne launches expanded R&D Systems AI-Engineered Designer Protein Portfolio

Bio-Techne Corporation, a global provider of life science tools, reagents, and diagnostic products, today announced the launch of new additions to its R&D Systems™ AI-Engineered Designer Protein portfolio, designed to improve reproducibility and performance across advanced cell culture and cell therapy development workflows.

From Bio-Techne 8 Jul 2026

FDA approves new therapy for double-positive metastatic breast cancer

The U.S. Food and Drug Administration (FDA) has approved a new therapy regimen for patients with "double-positive" metastatic breast cancer based on results of the phase 3 PATINA study led by Otto Metzger, MD, Associate Medical Director of International Strategic Initiatives at Dana-Farber Cancer Institute.

6 Jul 2026

New spatially resolved transcriptomic map reveals how bone and muscle cells communicate

A new study generated one of the most comprehensive spatially resolved transcriptomic maps of cellular communication between bone and skeletal muscle in a young mouse.

6 Jul 2026

Targeted therapy doubles progression-free survival in rare bile duct cancer

Results of the ongoing eNRGy trial, a single-arm, multicenter, global phase 2 clinical trial evaluating zenocutuzumab in solid tumors positive for Neuregulin 1 (NRG1) gene fusions, reported manageable side effects and clinically meaningful efficacy – including a near doubling of progression-free survival compared to expectations with standard of care – in previously treated patients with advanced NRG1-positive cholangiocarcinoma.

2 Jul 2026

Researchers develop novel strategy to selectively target tumor microenvironments

A new collaborative study reports the discovery and application of a novel therapeutic strategy to selectively target EGFR and other kinases with controlled release in tumor microenvironments to improve therapeutic efficacy, with promising results.

25 Jun 2026

New cell culture method allows targeted study of antibody regulation

For the immune system to effectively combat pathogens, antibody responses must be precisely controlled. So-called follicular regulatory T cells (Tfr cells) play a key role in this process by limiting excessive immune responses and helping to maintain immune tolerance.

25 Jun 2026

Gene linked to lower BMI points researchers toward a new obesity target

A review in Cardiology in Review highlights GPR75, a receptor for 20-HETE, as a promising therapeutic target for obesity and metabolic syndrome. Evidence from genetic studies, cell experiments, and mouse models suggests that blocking this pathway could influence weight gain, insulin resistance, hypertension, inflammation, and vascular dysfunction.

25 Jun 2026

FDA approves palbociclib combination for advanced HR-positive HER2-positive breast cancer

Today, Alliance Foundation Trials, LLC (AFT) was informed that the U.S. Food and Drug Administration has approved palbociclib in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for adult patients with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–positive (HER2+) locally advanced or metastatic breast cancer following induction treatment.

24 Jun 2026

Scientists identify unique receptor that accelerates early neuron growth

Cells have surface receptors that couple to proteins and other molecules to initiate or inhibit certain behaviors.

17 Jun 2026

Targeting immune cells could improve colorectal cancer treatments

Researchers at the Medical University of Vienna have described a mechanism in metastatic colorectal cancer that has received little attention to date: a key target of existing therapies, the so-called epidermal growth factor receptor (EGFR), is likely to affect more than just the cancer cells themselves.

17 Jun 2026

Tumor microenvironment drives drug resistance in lung cancer subtypes

A study by the University of Barcelona has discovered why the two main types of lung cancer — adenocarcinoma of the lung and squamous cell carcinoma — respond differently to anti-angiogenic therapy, that is, drugs that block the formation of new blood vessels that tumors need in order to grow.

15 Jun 2026

Single-dose gene therapy extends healthy lifespan in older mice

A research team from the Universitat Autònoma de Barcelona (UAB) has shown that a one-time administration of a gene therapy expressing the metabolic factor FGF21 can prolong health span in old mice.

15 Jun 2026